The mechanism of melanoma-associated thrombin activity and von willebrand factor release from endothelial cells

Journal of Investigative Dermatology

Volumn 130, Issue 9, 2010, Pages 2259-2268

  Kerk, Nina ^a   Strozyk, Elwira A ^b,c   Pöppelmann, Birgit ^a   Schneider, Stefan W ^b  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER PROCOAGULANT; ENOXAPARIN; N [N (3 CARBOXYOXIRANE 2 CARBONYL)LEUCYL]AGMATINE; PROTHROMBIN; SMALL INTERFERING RNA; THROMBIN; THROMBOPLASTIN; TINZAPARIN; VON WILLEBRAND FACTOR;

ARTICLE; CANCER CELL; DRUG MECHANISM; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; MELANOMA; METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION;

EID: 77955714406     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2010.136     Document Type: Article

References (62)

1. Amirkhosravi A, Meyer T, Chang JY et al. (2002) Tissue factor pathway inhibitor reduces experimental lung metastasis of B16 melanoma. Thromb Haemost 87:930-936
2. Amirkhosravi A, Mousa SA, Amaya M et al. (2003) Antimetastatic effect of tinzaparin, a low-molecular-weight heparin. J Thromb Haemost 1:1972-1976
3. Arora P, Ricks TK, Trejo J (2007) Protease-activated receptor signalling, endocytic sorting and dysregulation in cancer. J Cell Sci 120:921-928
4. Belting M, Ahamed J, Ruf W (2005) Signaling of the tissue factor coagulation pathway in angiogenesis and cancer. Arterioscler Thromb Vasc Biol 25:1545-1550
5. Boire A, Covic L, Agarwal A et al. (2005) PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell 120:303-313
6. Borsig L (2007) Antimetastatic activities of modified heparins: selectin inhibition by heparin attenuates metastasis. Semin Thromb Hemost 33:540-546
7. Borsig L (2008) The role of platelet activation in tumor metastasis. Expert Rev Anticancer Ther 8:1247-1255
8. Cadroy Y, Gaspin D, Dupouy D et al. (1996) Heparin reverses the procoagulant properties of stimulated endothelial cells. Thromb Hae-most 75:190-195
9. Castelli R, Porro F, Tarsia P (2004) The heparins and cancer: review of clinical trials and biological properties. Vasc Med 9:205-213
10. Damin D, Rosito M, Gus P et al. (2002) von Willebrand factor in colorectal cancer. Int J Colorectal Dis 17:42-45
11. Denis CV (2002) Molecular and cellular biology of von Willebrand factor. Int J Hematol 75:3-8
12. Donati MB, Gambacorti-Passerini C, Casali B et al. (1986) Cancer procoagulant in human tumor cells: evidence from melanoma patients. Cancer Res 46:6471-6474
13. Esmon CT, Esmon NL, Harris KW (1982) Complex formation between thrombin and thrombomodulin inhibits both thrombin-catalyzed fibrin formation and factor V activation. J Biol Chem 257:7944-7947
14. Esmon NL, Carroll RC, Esmon CT (1983) Thrombomodulin blocks the ability of thrombin to activate platelets. J Biol Chem 258:12238-12242
15. Falanga A, Gordon SG (1985) Isolation and characterization of cancer procoagulant: a cysteine proteinase from malignant tissue. Biochemistry (Mosc) 24:5558-5567
16. Falanga A, Panova-Noeva M, Russo L (2009) Procoagulant mechanisms in tumour cells. Best Pract Res Clin Haematol 22:49-60
17. Falanga A, Piccioli A (2005) Effect of anticoagulant drugs in cancer. Curr Opin Pulm Med 11:403-407
18. Fischer EG, Ruf W, Mueller BM (1995) Tissue factor-initiated thrombin generation activates the signaling thrombin receptor on malignant melanoma cells. Cancer Res 55:1629-1632
19. Geaquinto DL, Fernandes RS, Lima LG et al. (2008) Procoagulant properties of human MV3 melanoma cells. Braz J Med Biol Res 41:99-105
20. Goerge T, Barg A, Schnaeker E-M et al. (2006) Tumor-derived matrix metalloproteinase-1 targets endothelial proteinase-activated receptor 1 promoting endothelial cell activation. Cancer Res 66:7766-7774
21. Goerge T, Kleinerüschkamp F, Barg A et al. (2007) Microfluidic reveals generation of platelet-strings on tumor-activated endothelium. Thromb Haemost Aug 98:283-286
22. Goerge T, Niemeyer A, Rogge P et al. (2002) Secretion pores in human endothelial cells during acute hypoxia. J Membr Biol 187:203-211
23. Gordon SG, Cross BA (1981) A factor X-activating cysteine protease from malignant tissue. J Clin Invest 67:1665-1671
24. Gordon SG, Mielicki WP (1997) Cancer procoagulant: a factor X activator, tumor marker and growth factor from malignant tissue. Blood Coagul Fibrinolysis 8:73-86
25. Hanly AM, Hayanga A, Winter DC et al. (2005) Thrombomodulin: tumour biology and prognostic implications. Eur J Surg Oncol 31:217-220
26. Hanly AM, Redmond M, Winter DC et al. (2006) Thrombomodulin expression in colorectal carcinoma is protective and correlates with survival. Br J Cancer 94:1320-1325
27. Hemker HC, Béguin S (1990) Mode of action of unfractionated and low molecular weight heparins on the generation of thrombin in plasma. Haemostasis 20:81-92
28. Hosaka Y, Higuchi T, Tsumagari M et al. (2000) Inhibition of invasion and experimental metastasis of murine melanoma cells by human soluble thrombomodulin. Cancer Lett 161:231-240
29. Hu L, Lee M, Campbell W et al. (2004) Role of endogenous thrombin in tumor implantation, seeding, and spontaneous metastasis. Blood 104:2746-2751
30. Huck V, Niemeyer A, Goerge T et al. (2007) Delay of acute intracellular pH recovery after acidosis decreases endothelial cell activation. J Cell Physiol 211:399-409
31. Ilkovitch D, Lopez DM (2008) Immune modulation by melanoma-derived factors. Exp Dermatol 17:977-985
32. Im JH, Fu W, Wang H et al. (2004) Coagulation facilitates tumor cell spreading in the pulmonary vasculature during early metastatic colony formation. Cancer Res 64:8613-8619
33. Kakkar AK (2009) Antithrombotic therapy and survival in cancer patients. Best Pract Res Clin Haematol 22:147-151
34. Kakkar AK, Levine MN, Kadziola Z et al. (2004) Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol 22:1944-1948
35. Karpatkin S, Pearlstein E, Ambrogio C et al. (1988) Role of adhesive proteins in platelet tumor interaction in vitro and metastasis formation in vivo. J Clin Invest 81:1012-1019
36. Klerk CPW, Smorenburg SM, Otten H-M et al. (2005) The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 23:2130-2135
37. Lazo-Langner A, Goss GD, Spaans JN et al. (2007) The effect of low-molecular-weight heparin on cancer survival. A systematic review and meta-analysis of randomized trials. J Thromb Haemost 5:729-737
38. Lee AYY, Levine MN, Baker RI et al. (2003) Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboem-bolism in patients with cancer. N Engl J Med 349:146-153
39. Lee AYY, Rickles FR, Julian JA et al. (2005) Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol 23:2123-2129
40. Loffek S, Zigrino P, Angel P et al. (2005) High invasive melanoma cells induce matrix metalloproteinase-1 synthesis in fibroblasts by interleukin-1[alpha] and basic fibroblast growth factor-mediated mechanisms. J Invest Dermatol 124:638-643
41. Lorigan P, Eisen T, Hauschild A (2008) Systemic therapy for metastatic malignant melanoma\from deeply disappointing to bright future? Exp Dermatol 17:383-394
42. Ludwig RJ, Alban S, Bistrian R et al. (2006) The ability of different forms of heparins to suppress P-selectin function in vitro correlates to their inhibitory capacity on bloodborne metastasis in vivo. Thromb Haemost 95:535-540
43. Ludwig RJ, Boehme B, Podda M et al. (2004) Endothelial P-selectin as a target of heparin action in experimental melanoma lung metastasis. Cancer Res 64:2743-2750
44. Mackman N (2004) Role of tissue factor in hemostasis, thrombosis, and vascular development. Arterioscler Thromb Vasc Biol 24:1015-1022
45. Martinez-Sales V, Vila V, Reganon E et al. (2003) Effect of unfractionated heparin and a low molecular weight heparin (enoxaparin) on coagulant activity of cultured human endothelial cells. Haematologica 88:694-699
46. Melnikova V, Villares G, Bar-Eli M (2008) Emerging roles of PAR-1 and PAFR in melanoma metastasis. Cancer Microenviron 1:103-111
47. Mueller BM, Reisfeld RA, Edgington TS et al. (1992) Expression of tissue factor by melanoma cells promotes efficient hematogenous metastasis. Proc Natl Acad Sci USA 89:11832-11836
48. Nierodzik ML, Chen K, Takeshita K et al. (1998) Protease-activated receptor 1 (PAR-1) is required and rate-limiting for thrombin-enhanced experimental pulmonary metastasis. Blood 92:3694-3700
49. Nierodzik ML, Kajumo F, Karpatkin S (1992) Effect of thrombin treatment of tumor-cells on adhesion of tumor-cells to platelets in vitro and tumor-metastasis in vivo. Cancer Res 52:3267-3272
50. Nierodzik ML, Klepfish A, Karpatkin S (1995) Role of platelets, thrombin, integrin IIb-IIIa, fibronectin and von Willebrand factor on tumor adhesion in vitro and metastasis in vivo. Thromb Haemost 74:282-290
51. Niers TMH, Klerk CPW, DiNisio M et al. (2007) Mechanisms of heparin induced anticancer activity in experimental cancer models. Crit Rev Oncol Hematol 61:195-207
52. Rickles FR, Patierno S, Fernandez PM (2003) Tissue factor, thrombin, and cancer. Chest 124:58S-68S
53. Rickles FR, Shoji M, Abe K (2001) The role of the hemostatic system in tumor growth, metastasis, and angiogenesis: tissue factor is a bifunctional molecule capable of inducing both fibrin deposition and angiogenesis in cancer. Int J Hematol 73:145-150
54. Ruggeri ZM (2003) von Willebrand factor, platelets and endothelial cell interactions. J Thromb Haemost 1:1335-1342
55. Schneider SW, Nuschele S, Wixforth A et al. (2007) Shear-induced unfolding triggers adhesion of von Willebrand factor fibers. Proc Natl Acad Sci USA 104:7899-7903
56. Simonis D, Christ K, Alban S et al. (2007) Affinity and kinetics of different heparins binding to P-and L-selectin. Semin Thromb Hemost 33:534-539
57. Stevenson JL, Choi SH, Varki A (2005) Differential metastasis inhibition by clinically relevant levels of heparins\correlation with selectin inhibition, not antithrombotic activity. Clin Cancer Res 11:7003-7011
58. Stevenson JL, Varki A, Borsig L (2007) Heparin attenuates metastasis mainly due to inhibition of P-and L-selectin, but non-anticoagulant heparins can have additional effects. Thromb Res 120:S107-11
59. Tellez C, Bar-Eli M (2003) Role and regulation of the thrombin receptor (PAR-1) in human melanoma. Oncogene 22:3130-3137
60. Terraube V, Pendu R, Baruch D et al. (2006) Increased metastatic potential of tumor cells in von Willebrand factor-deficient mice. J Thromb Haemost 4:519-526
61. Trousseau A (1865) Phlegmasia alba dolens. Clinique medicale de l'Hotel-Dieu de Paris. The New Sydenham Society 3:654-712
62. Zhang Y, Weiler-Guettler H, Chen J et al. (1998) Thrombomodulin modulates growth of tumor cells independent of its anticoagulant activity. J Clin Invest 101:1301-1309